How Design Wins Medtech Markets
- Contributor - Bhavana Ramesh
- 6 min read
Share:
Every few months, a report lands on the desks of medtech founders promising to explain why capital is so hard to raise in this sector. The reports are usually thorough on financing and silent on design. The latest one, from India’s Department of Pharmaceuticals, is no exception.
What the Numbers Actually Say
The report puts hard figures on what founders already know. India’s medical device market sits at roughly $12 billion and is growing at about 15% annually, with the Department’s own projections pointing to $50 billion by FY30. Multinationals still control 80–90% of the high-end specialized segment. Imports cover roughly 60% of domestic consumption. Developing an innovative device takes five to fifteen years and costs anywhere from $100 million to $1 billion. The study surveyed manufacturers, promoters, incubators, and venture capital firms, and more than four in five respondents — 82.6%, specifically — called for government guarantees, including assured government purchases, to make investment less risky. The study’s own recommendations went further still: milestone-based funding, shared testing infrastructure, dedicated device parks, and faster regulatory clearances.
These figures are accurate. The structural barriers are real. Capital is scarce, supply chains are fragmented, and regulatory timelines are long.
The Variable Missing From the Risk Model
What the report never asks is whether the device itself is any good to use. Human factors, industrial design, and sound engineering never appear as variables in the risk equation, even though they’re controllable from day one — well before a funding round or regulatory submission ever materializes. That omission matters. Design is not a cosmetic layer applied after the engineering is done. It’s a direct mitigant for technology risk, market risk, and regulatory liability risk. In the best cases, it creates new addressable market or directly unlocks funding and distribution. This is the argument we’ve built our practice around, and the four projects below are the evidence, not the pitch. A device that fails in real clinical conditions, that patients refuse to wear, or that triggers adverse events from poor user experience will sink a company regardless of how favorable its grant terms are.
Small Enough to Disappear, Reliable Enough to Trust
One of the clearest examples is Monitra Upbeat, a continuous cardiac monitoring patch we developed with Monitra Healthcare. Arrhythmia is difficult to diagnose because episodes can be transient, separated by days, weeks, or months. A standard ECG in a clinic will miss what it doesn’t record. Monitra needed a patch-based system that patients would wear 24 hours a day, at home or at work, for up to a week, recording every heartbeat continuously. That clinical value proposition only works if the device actually stays on the body — if the patient doesn’t remove it out of discomfort or embarrassment.
We shaped the device as a thin, capsule-like form that sits just above the rib cage, low enough to disappear under clothing. Privacy wasn’t a secondary concern. If patients saw a visible bulge under a shirt, compliance would collapse, and the data Monitra needed to build its clinical evidence base would never exist. The enclosure is soft, built for sleep and daily movement, and rated to IP67 so patients can shower or swim without removing it. Application is three steps a nurse can execute at discharge with no ambiguity: stick the patch on like a bandage, snap the recorder onto the dock, pair with a phone app. The white-and-blue palette and soft surface transitions were chosen specifically to signal hygiene and clinical trustworthiness, and the logo doubles as a functional status indicator — solving utility and brand visibility in the same decision.
Monitra was able to demo the product, gather real user feedback, and move toward production without restarting the design when technology or business requirements shifted mid-program. The comfort and discretion weren’t aesthetic add-ons. They were the precondition for the continuous data that became Monitra’s clinical evidence base — which is what investors ultimately funded.
Four Vitals, One Object, Ahead of Silicon Valley
A different kind of proof came from BPL LifePhone Plus, a project we ran with BPL Medical and Intel. India carries one of the world’s highest burdens of cardiovascular disease and diabetes, but the gap was access, not knowledge. Diagnostics lived inside large hospitals, and consumer devices on the market each tracked only one parameter. Intel wanted to extend its mobile computing platform into healthcare, and the brief was to integrate ECG, blood glucose monitoring, activity tracking, and later blood pressure into a single compact device that people would actually carry, use, and trust.
We designed the form to be minimal and pocketable, with thumb placement that forces a specific hand gesture through muscle memory rather than instruction. The electrodes protrude for torso placement, while flat finger electrodes carry dimples for a natural grip and repeatable accuracy on a self-administered clinical reading. We eliminated visible side shutlines for a seamless enclosure — an explicit choice to raise perceived reliability in a device asking people to trust it with health data. The unibody chassis allowed partial assembly and testing at the factory level before final finishing, improving both efficiency and quality control, and the blood glucose sensor was thermally isolated to protect measurement accuracy.
The result was the first multi-parameter mHealth product in the world. It beat internationally funded X-Prize and Tricorder contenders, including Scanadu Scout, to market. It launched domestically, was exported overseas, and became BPL’s most successful portable personal ECG device, validating Intel’s broader mobile-healthcare vision. According to a company interview, it also won six global product innovation awards in medtech — we haven’t independently verified that figure, but the trophy count isn’t really the point. The point is that usability and industrial-design credibility were the mechanism for winning the category, not a layer added after the engineering was finished.
See how we approach industrial design and product engineering for regulated devices, or browse more of our health & life sciences work.
Built for the Hardest User in the Room
There’s also value in looking outside our own portfolio for reinforcement. iMedrix’s KardioScreen offers a useful parallel — we didn’t design this one, but it illustrates the same principle. It’s a mobile, connected six-to-twelve-lead ECG device built to be operated by non-specialists — community health workers, ambulance staff — in field conditions, not only by trained cardiologists in hospitals. It’s FDA 510(k) cleared and CE certified, has recorded over 450,000 ECGs across 15 countries, and is used by more than 50 hospitals and clinics across Asia and ASEAN. It serves as an access-to-care partner for Medtronic, Philips, and Siemens, and won the Medtronic APAC Innovation Challenge in 2022.
The design brief was human-factors-first: built for the least-trained, harshest-condition user, not the ideal one. That decision produced a usage record large enough to matter in a funding conversation. When a product is built for the hardest user, the usage data that accumulates becomes its own de-risking asset — no pitch deck required.
A Headset Nobody Was Afraid to Wear
With Elisar AVA, design functioned as market creation. Elisar is an ophthalmology startup incubated inside a leading Indian eye hospital, and it approached eyecare with a tech-startup’s instincts rather than a traditional device company’s caution. Glaucoma testing through perimetry traditionally requires a dedicated exam lane and expensive benchtop equipment, which locks the test inside large hospitals and out of reach for most patients. The brief was to build something portable, low-cost, and operable by a semi-skilled technician rather than a trained perimetrist.
We shaped the device like a VR headset. At the time, VR headsets were becoming familiar in India — common enough on trains and buses that patients and technicians would recognize the form instantly rather than fear it. That familiarity defused the anxiety that comes with an unfamiliar clinical procedure. It also carried a technical bonus: leaning on a smartphone’s own processing power meant sidestepping dedicated, expensive hardware, which cut cost and let the team iterate faster. The deep black finish wasn’t just an aesthetic choice — glaucoma testing needs a dark environment, and the black enclosure prevents light leaks that would compromise accuracy even under bright clinic lighting.
Because the device had to travel to remote clinics on two-wheelers and in backpacks, we engineered it to survive vibration, drops, and general wear, choosing materials and tolerances carefully to protect precision internal assemblies without sacrificing manufacturability. We also built modularity into the platform so Elisar could swap in newer phone models as the underlying hardware aged out, protecting the long-term investment in the platform itself.
The result: the first solution able to perform perimetry without a traditional exam lane or high-cost capital equipment. A test that used to require a hospital visit can now travel to the patient, in a city hospital or a remote village clinic. Investors and partners pay attention when a product expands who the customer even is, not just when it improves an existing product — and that expansion started as an industrial-design decision as much as an optical one.
The Clearest Proof: Design That Opened a Funding Door
The strongest and most literal evidence for this whole argument came with Elisar NOA, which we built for Elisar after AVA. NOA — Near-eye Objective Assessment — is a next-generation diagnostic platform, not a screening add-on. It integrates high-resolution OCT imaging and advanced optical biometry into a single lightweight, head-mounted device, aimed at replacing large benchtop diagnostic machines. OCT provides cross-sectional retinal imaging used to detect glaucoma, macular degeneration, and diabetic retinopathy. Optical biometry measures axial length, corneal curvature, lens thickness, and anterior chamber depth, used for intraocular lens calculations in cataract surgery and for flagging anatomical risk factors.
The program had three explicit goals: build a scalable platform for eyecare diagnostics, engineer modularity to support multiple price and feature tiers, and design every part for minimal upfront tooling investment to hit the shortest possible launch timeline. We ran user studies across three clinical settings — single-room clinics, community hospitals, advanced eye-care centers — and found three distinct constraints. Doctors needed flexibility in where the device could sit, given tight space. Patients disliked leaning into bulky machines or holding uncomfortable postures. Clinic owners were conservative about new technology and sharply cost-sensitive.
We designed four mounting configurations — floor, wall, ceiling, chair — each optimized for space efficiency or patient comfort, built on a common platform architecture so the same core device adapts to very different clinic layouts. That modularity enabled a tiered product line: NOA OCT for retinal imaging alone, NOA Biometer for axial length and IOL calculations alone, and NOA Plus combining both, so an entry-level configuration could stay affordable while still leaving room to upgrade. Patient comfort was engineered directly into throughput: a natural seated posture, minimized movement between the OCT and biometry tests, and 80,000-scans-per-second imaging speed to cut total chair time — which helps patients and clinic throughput at once. Instead of injection molding or RIM, both of which demand expensive tooling and long lead times, every part was designed for vacuum casting, which lowered upfront investment, sped up prototyping, and still delivered surfaces and finish comparable to premium medical devices.
The finalized prototype showed at a major international ophthalmology conference. The reception turned a conservative audience into booked demos, which led to accelerated production planning and a clear path to commercialization. Elisar’s own account of the project doesn’t leave this to interpretation: the finished design gave a skeptical trade-show room reason to trust the underlying optics, and that credibility is what pulled new funding and distribution conversations into motion. This isn’t an inference we’re drawing. It’s what the project record states outright — the design work directly caused the funding outcome.
Curious what a design-first approach could unlock for your own device pipeline?
Book a roadmap call and let’s talk specifics.
The Lever Founders Already Hold
The DoP report’s recommendations are worth pursuing. Milestone-based funding, blended finance, shared testing facilities, faster regulatory clearances, dedicated medical device parks — all of it would help. But every one of those requires policy to move, committees to convene, budgets to clear. Design and human factors are a lever a founder can pull immediately, with the team already in the room, before a funding round is even a live conversation.
Good design de-risks the exact things investors are pricing. It makes devices work reliably in real conditions, not just in the lab. It drives adoption by patients and clinicians instead of assuming it. It reduces the liability exposure that comes from misuse triggered by poor user experience. And in the best cases — Elisar NOA being the clearest one we’ve seen — it creates new market or directly unlocks capital.
India’s medtech sector doesn’t just need cheaper capital or friendlier policy, though both would help. It needs more devices that are good enough, usable enough, and trustworthy enough that funding starts chasing the product instead of the other way around. That’s a variable founders control. The only question is whether they treat it as one.
This is the work we do at Bang Design — industrial design, product engineering, and DFMA and production transition for founders who’d rather build the thing worth funding than wait for the policy environment to catch up. Take a look at our full body of work, see our plans, or start a project with us directly.